General Stock Ideas

[gfp927z]

Ombow, That type of 'article' is one of the reasons I have little/no faith in CYDY. The article smacks of being a paid-for pump piece in the guise of a news article, complete with an anonymous author ('chopperone'). The past videos I've seen on YouTube pertaining to CYDY also don't pass the smell test, and seem like paid commercials for CYDY, and as with this 'article', are they done in a deceptive way. These days internet news sites get paid for running this type of 'article'.

While CYDY might ultimately succeed, I'll be watching from the sidelines. The CEO seems like a shifty little creep, and at almost $4 bil, the market cap is already assuming success. The share count is close to 'blown out' status (600 mil shares), they don't have much cash, and the annual loss is a relatively huge $159 mil.

The full Phase 3 data for the severe trial is all that matters right now, everything else is background noise. But what the manufactured 'articles' and videos tell us is that this is a deceptive CEO/company that you can't trust.



>>> How to give the economy a shot, with an actual shot.


Zero Hedge

BY CHOPPERONE

FEB 02, 2021


https://www.zerohedge.com/news/2021-02-02/how-give-economy-shot-shot


Joe Biden has appointed the eminently qualified Janet Woodcock as interim head of the FDA. Dr. Woodcock may get the chance to save thousands of lives as well as the entire U.S. economy. That’s the type of accomplishment that would not only warrant a permanent leadership position but perhaps also a place in history.

Overflowing intensive care units across the nation led to lockdowns which have permanently damaged the economy. Nine months after achieving near full employment, over 20 million Americans now receive weekly unemployment checks. A recent report stated that over 100,000 restaurants will shortly close - a high mortality cost, indeed. The massive service economy employs a preponderance of Americans.

Now politicians scramble to provide life-supporting bailouts financed by debt. If the stimulus bill passes, the annual federal budget deficit soars to $5 trillion, up from $3.3 trillion last year. The government will have to fund this spree by issuing new treasury debt just as a record $5.8 trillion of current debt has to be refinanced. Vital tax revenues will suffer if the economy doesn’t return to health quickly. These are truly scary financial conditions.

Meanwhile we dither in the face of Covid. The prior administration, under severe political pressure, approved a string of drugs that either are not effective or are too costly and cumbersome to administer. Some have shaky safety profiles. The “Recovery” trial for convalescent plasma, touted last fall in a public ceremony by the FDA, was just abandoned. Vaccines do nothing for current patients and no one knows how long they provide immunity or whether they work against new viral mutations. As WSJ reporter Joseph Walker recently highlighted in his article “Companies Race to Develop Drugs to Stay Ahead of Corona Virus Mutations,” companies are still struggling to create a drug that checks all the boxes necessary to qualify as a real solution.

Within a few weeks, the FDA is set to decide on a therapeutic that appears to do just that. It is one of several promising drugs that you haven’t heard of because they don’t hail from big pharma. The government supports the largest pharmaceutical companies with investment dollars and expedited approvals, while emerging companies struggle to survive the FDAs trial process.

We now have data that shows that an immunomodulator monoclonal antibody greatly reduces mortality and gets patients out of the hospital. It is taken as an easy to administer subcutaneous shot 2 times in an outpatient setting.

The drug is leronlimab, branded as Vyrologix, and owned by CytoDyn (CYDY). An HIV drug, it has been around for years, has a flawless safety record and just completed a phase 3 trial for severe to critical Covid-19 patients. In its phase 2 trial for mild to moderate Covid patients, using the “NEWS 2” criteria developed by the Royal College of Physicians, a statistically significant 50% of patients experienced beneficial improvement versus 20% in the placebo group. Importantly, the FDA has given the drug an open label extension allowing it to be administered in emergency situations while the company assembles the data from the phase 3 trial,

Leronlimab has had real world success. It was widely used on critically ill patients under the FDAs Emergency Indication (EIND) program which allows doctors to use an experimental drug in dire conditions. The consensus among those doctors is that leronlimab appears to make a difference in 3 days. The trial will seek to verify this. A number of doctors have published peer reviewed articles describing its effectiveness including Dr. Bruce Patterson of IncellDX, another under-the-radar company that produces companion diagnostic tests to determine exactly how a drug is working in real-time. He was among the group who first determined that leronlimab might work for Covid. Then, he used his tests to watch the drug in action. He’s currently researching how to treat “long haulers.” Long haulers are a subset of Covid patients who can’t shake the disease well after the virus has subsided. The long hauler that we should worry about most is the U.S. economy whose immune system is already compromised by the weak fiscal situation. Maybe we’ve found a Covid treatment that works immediately while the long process of administering vaccines continues.

<<<